Lymphoma News and Research RSS Feed - Lymphoma News and Research

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Bone loss linked with ALL therapy occurs during first month of treatment

Bone loss linked with ALL therapy occurs during first month of treatment

Investigators at Children's Hospital Los Angeles have found that significant bone loss - a side effect of chemotherapy for acute lymphoblastic leukemia (ALL) - occurs during the first month of treatment, far earlier than previously assumed. Results of the study will be available online February 4, in advance of publication in the journal Bone. [More]
ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. [More]
HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA Bioscience International President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. [More]
Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

Young African Americans, Hispanics fare worse when faced with Hodgkin lymphoma

African American and Hispanic adolescents and young adults fare far worse than their white counterparts when faced with a mostly curable type of cancer, Hodgkin lymphoma, a study by a UC Davis epidemiologist has found. [More]
Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others. [More]
Researchers discover potential candidates for development of novel targeted therapies for blood cancers

Researchers discover potential candidates for development of novel targeted therapies for blood cancers

A research team from the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute has discovered a new class of small-molecule compounds that are good candidates for development of novel targeted therapies in the treatment of leukemia and lymphoma. [More]
Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Newly drafted consensus statement promotes widespread use of HPV vaccines to prevent cancer

Leaders of several cancer centers designated by the National Cancer Institute have united to support human papillomavirus vaccination. Among them is Cheryl Willman, MD, Director and CEO of the University of New Mexico Comprehensive Cancer Center. [More]
African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

African-American pediatric lymphoma patients have inferior outcomes compared to white and Hispanic peers

Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine today published a study showing that African-American pediatric Hodgkin lymphoma patients have inferior overall survival to their white and Hispanic peers. [More]
Researchers explore ways to use light to combat cancer

Researchers explore ways to use light to combat cancer

Immunotherapy is one of the hottest emerging areas of cancer research. After all, using the body's own cells to fight cancer can be more effective and less invasive than flooding the entire system with toxic chemicals. [More]
Interictal discharges have neuropsychological effects in rolandic epilepsy

Interictal discharges have neuropsychological effects in rolandic epilepsy

Centrotemporal spikes experienced between seizures by children with rolandic epilepsy may disrupt functional brain networks and contribute to language, behaviour and cognitive problems, research suggests. [More]
Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada approves immunotherapy clinical study to treat Epstein-Barr virus-related lymphomas

Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus (EBV) through adoptive cellular immunotherapy that is specific to EBV. [More]
Researchers identify origins of aggressive childhood lymphoma

Researchers identify origins of aggressive childhood lymphoma

The origins of a type of aggressive childhood lymphoma have been found, giving hope that new drugs could be designed to prevent the disease coming back after treatment. [More]
Scientists identify origins of anaplastic large cell lymphoma

Scientists identify origins of anaplastic large cell lymphoma

Anaplastic large cell lymphoma (ALCL) is a very aggressive cancer of the blood, which usually occurs as a tumour in lymph nodes, the skin, the lungs, the liver, and in soft tissue, and mainly affects children and young adults. [More]
New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment for the cancer that in many cases would be effective. [More]
Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists devise new treatments for neuroblastoma

Pediatric oncologists from The Children's Hospital of Philadelphia have reported their latest results in devising new treatments for stubbornly deadly forms of the childhood cancer neuroblastoma. [More]
Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Toxins in staphylococcus bacteria can help cancer cells gain control over healthy cells

Our skin is covered in millions of bacteria and most of them help keep us healthy. However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells. [More]
New TAU study offers tangible hope of curing Mantle Cell Lymphoma

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

With a median survival rate of just five to seven years, Mantle Cell Lymphoma (MCL) is considered the most aggressive known blood cancer -- and available therapies are scarce. Three thousand Americans are diagnosed with MCL every year, and despite progress in personalized therapies to treat metastases elsewhere in the body, systemic therapeutic drug delivery to cancerous blood cells continues to challenge the world of cancer research. [More]
Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA. [More]
New oral breast cancer drug has potential to combat other types of cancer

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology. [More]
Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals obtains FDA approval to begin Phase 1/2 study in AML and MDS patients

Rich Pharmaceuticals, Inc. is pleased to announce that the Company has received approval from the U.S. Food and Drug Administration to commence its Phase 1/2 clinical for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients. [More]
Advertisement
Advertisement